Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Serious adverse events that triggered an FDA clinical hold on two of Idenix's hepatitis C programs - IDX184 and IDX320 - could have been caused by an unforeseen effect of combining the drugs, as opposed to a defect with one of the individual drugs